Unknown PHASE4 INTERVENTIONAL 2-arm NCT02864472

Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose

Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose

Sponsor: Novartis

Conditions Age-related Macular Degeneration

Interventions PDT Ranibizumab ranibizumab PRN

Updated 6 times since 2017 Last updated: Aug 10, 2016 Started: Sep 30, 2016 Primary completion: Jun 30, 2018 Completion: Jan 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Age-related Macular Degeneration and is currently ongoing. Novartis leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Feb 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE4

First recorded

Sep 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Seoul National University Hospital

Data source: Seoul National University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.